- Home
- HOOK vs LPCN Comparison
HOOK vs LPCN Comparison
Compare HOOK & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- LPCN
- Stock Information
- Founded
- HOOK 2011
- LPCN 1997
- Country
- HOOK United States
- LPCN United States
- Employees
- HOOK N/A
- LPCN N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- HOOK Health Care
- LPCN Health Care
- Exchange
- HOOK Nasdaq
- LPCN Nasdaq
- Market Cap
- HOOK 15.3M
- LPCN 16.1M
- IPO Year
- HOOK 2019
- LPCN N/A
- Fundamental
- Price
- HOOK $1.20
- LPCN $3.20
- Analyst Decision
- HOOK Buy
- LPCN Strong Buy
- Analyst Count
- HOOK 4
- LPCN 2
- Target Price
- HOOK $10.67
- LPCN $9.00
- AVG Volume (30 Days)
- HOOK 65.1K
- LPCN 60.6K
- Earning Date
- HOOK 08-07-2025
- LPCN 08-07-2025
- Dividend Yield
- HOOK N/A
- LPCN N/A
- EPS Growth
- HOOK N/A
- LPCN N/A
- EPS
- HOOK N/A
- LPCN N/A
- Revenue
- HOOK $9,351,000.00
- LPCN $3,674,834.00
- Revenue This Year
- HOOK N/A
- LPCN N/A
- Revenue Next Year
- HOOK N/A
- LPCN N/A
- P/E Ratio
- HOOK N/A
- LPCN N/A
- Revenue Growth
- HOOK N/A
- LPCN N/A
- 52 Week Low
- HOOK $0.72
- LPCN $2.68
- 52 Week High
- HOOK $6.77
- LPCN $7.90
- Technical
- Relative Strength Index (RSI)
- HOOK 39.18
- LPCN 52.85
- Support Level
- HOOK $1.13
- LPCN $3.09
- Resistance Level
- HOOK $1.35
- LPCN $3.34
- Average True Range (ATR)
- HOOK 0.06
- LPCN 0.17
- MACD
- HOOK -0.01
- LPCN 0.01
- Stochastic Oscillator
- HOOK 40.64
- LPCN 43.31
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.